{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:19:05Z","timestamp":1785417545944,"version":"3.56.0"},"reference-count":50,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Patients with synchronous malignancies can be problematic to diagnose and manage because workup and therapeutic targeting for each individual malignancy must be coordinated carefully. This report presents a patient with concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) managed with concomitant venetoclax and imatinib. Because imatinib is a moderate cytochrome P450 3A4 inhibitor, close monitoring is required when using with a substrate of 3A4 such as venetoclax. Although the target dose of venetoclax is 400 mg, it was capped at 100 mg due to the interaction. Despite the interaction and possible enhancement of toxicities, the patient has tolerated therapy well, and both diseases have responded to this novel approach. In addition, because aberrant BCL-2 activity has been implicated in CML, the use of venetoclax may contribute to success in the management of this patient\u2019s CML. This case report represents the safe concomitant use of venetoclax and imatinib in a patient with synchronous CML and CLL.<\/jats:p>","DOI":"10.6004\/jnccn.2022.7069","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T20:12:13Z","timestamp":1676491933000},"page":"102-107","source":"Crossref","is-referenced-by-count":6,"title":["Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report"],"prefix":"10.6004","volume":"21","author":[{"given":"Eugene R.","family":"Przespolewski","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Baron","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshid","family":"Kashef","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"},{"name":"Kaleida Health, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila N.","family":"Jani Sait","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thompson","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman RR","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE,  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997\u20131007.10.1056\/NEJMoa1315226"},{"key":"B2","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM,  Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425\u20132437.10.1056\/NEJMoa1509388"},{"key":"B3","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer K","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J,  Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380:2225\u20132236.10.1056\/NEJMoa1815281"},{"key":"B4","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts AW","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM,  Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374:311\u2013322.10.1056\/NEJMoa1513257"},{"key":"B5","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd JC","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S,  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213\u2013223.10.1056\/NEJMoa1400376"},{"key":"B6","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F,  Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917\u2013927.10.1056\/NEJMoa1609324"},{"key":"B7","series-title":"Blood","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes TP","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S,  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758\u20133765.10.1182\/blood-2010-03-273979"},{"key":"B8","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM,  Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333\u20132340.10.1200\/JCO.2015.64.8899"},{"key":"B9","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA,  Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35:440\u2013453.10.1038\/s41375-020-01111-2"},{"key":"B10","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW,  Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018;36:231\u2013237.10.1200\/JCO.2017.74.7162"},{"key":"B11","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT,  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966\u2013984.10.1038\/s41375-020-0776-2"},{"key":"B12","series-title":"Blood","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes T","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A,  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28\u201337.10.1182\/blood-2006-01-0092"},{"key":"B13","series-title":"Am J Hematol","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah NP","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C,  Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 2016;91:869\u2013874.10.1002\/ajh.24423"},{"key":"B14","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles FJ","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J,  Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107\u2013112.10.1038\/leu.2012.181"},{"key":"B15","series-title":"Am J Hematol","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM,  Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol 2016;91:1206\u20131214.10.1002\/ajh.24536"},{"key":"B16","series-title":"Blood","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J,  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018;132:393\u2013404.10.1182\/blood-2016-09-739086"},{"key":"B17","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes TP","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE,  Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 2019;381:2315\u20132326.10.1056\/NEJMoa1902328"},{"key":"B18","series-title":"Ann Hematol","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s00277-018-3413-7","article-title":"Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?","volume":"97","author":"Osorio S","year":"2018","unstructured":"Osorio S, Escudero-Vilaplana V, G\u00f3mez-Centuri\u00f3n I,  Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem? Ann Hematol 2018;97:2089\u20132098.10.1007\/s00277-018-3413-7"},{"key":"B19","series-title":"Oncotarget","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.18632\/oncotarget.1925","article-title":"The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors","volume":"5","author":"Ko TK","year":"2014","unstructured":"Ko TK, Chuah CT, Huang JW,  The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget 2014;5:9033\u20139038.10.18632\/oncotarget.1925"},{"key":"B20","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V,  Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617\u2013629.10.1056\/NEJMoa2012971"},{"key":"B21","series-title":"Cancer Discov","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan R","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM,  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014;4:362\u2013375.10.1158\/2159-8290.CD-13-0609"},{"key":"B22","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-15-0364","article-title":"BCL-2 antagonism to target the intrinsic mitochondrial pathway of apoptosis","volume":"21","author":"Gibson CJ","year":"2015","unstructured":"Gibson CJ, Davids MS. BCL-2 antagonism to target the intrinsic mitochondrial pathway of apoptosis. Clin Cancer Res 2015;21:5021\u20135029.10.1158\/1078-0432.CCR-15-0364"},{"key":"B23","series-title":"J Exp Med","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Horita M","year":"2000","unstructured":"Horita M, Andreu EJ, Benito A,  Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977\u2013984.10.1084\/jem.191.6.977"},{"key":"B24","series-title":"Cell Stem Cell","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff DJ","year":"2013","unstructured":"Goff DJ, Court Recart A, Sadarangani A,  A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013;12:316\u2013328.10.1016\/j.stem.2012.12.011"},{"key":"B25","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1002\/cncr.27568","article-title":"Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34- positive compartment","volume":"118","author":"Quint\u00e1s-Cardama A","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Qiu YH, Post SM,  Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34- positive compartment. Cancer 2012;118:5283\u20135292.10.1002\/cncr.27568"},{"key":"B26","series-title":"Sci Transl Med","doi-asserted-by":"publisher","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter BZ","year":"2016","unstructured":"Carter BZ, Mak PY, Mu H,  Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 2016;8:355ra117.10.1126\/scitranslmed.aag1180"},{"key":"B27","series-title":"Blood","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5428.5428","article-title":"Anti-leukemic effects of venetoclax on Philadelphia chromosome positive leukemia cells [abstract]","volume":"128","author":"Okabe S","year":"2016","unstructured":"Okabe S, Tauchi T, Tanaka Y,  Anti-leukemic effects of venetoclax on Philadelphia chromosome positive leukemia cells [abstract]. Blood 2016;128:Abstract 631.10.1182\/blood.V128.22.5428.5428"},{"key":"B28","series-title":"Lancet Oncol","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf O","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M,  Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020;21:1188\u20131200.10.1016\/S1470-2045(20)30443-5"},{"key":"B29","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax- rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater AP","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P,  Fixed duration of venetoclax- rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol 2019;37:269\u2013277.10.1200\/JCO.18.01580"},{"key":"B30","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour JF","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B,  Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378:1107\u20131120.10.1056\/NEJMoa1713976"},{"key":"B31","series-title":"Eur J Clin Pharmacol","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","article-title":"Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics","volume":"74","author":"Freise KJ","year":"2018","unstructured":"Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol 2018;74:413\u2013421.10.1007\/s00228-017-2403-3"},{"key":"B32","series-title":"Clin Ther","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal SK","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J,  Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 2017;39:359\u2013367.10.1016\/j.clinthera.2017.01.003"},{"key":"B33","series-title":"Br J Clin Pharmacol","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal SK","year":"2017","unstructured":"Agarwal SK, Salem AH, Danilov AV,  Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol 2017;83:846\u2013854.10.1111\/bcp.13175"},{"key":"B34","series-title":"Br J Pharmacol","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula AM","year":"2012","unstructured":"Filppula AM, Laitila J, Neuvonen PJ,  Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 2012;165:2787\u20132798.10.1111\/j.1476-5381.2011.01732.x"},{"key":"B35","series-title":"Clin Pharmacokinet","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng B","year":"2005","unstructured":"Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879\u2013894.10.2165\/00003088-200544090-00001"},{"key":"B36","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","article-title":"Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"27","author":"Tsimberidou AM","year":"2009","unstructured":"Tsimberidou AM, Wen S, McLaughlin P,  Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol 2009;27:904\u2013910.10.1200\/JCO.2008.17.5398"},{"key":"B37","series-title":"Br J Haematol","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/bjh.14667","article-title":"Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma","volume":"178","author":"Martin P","year":"2017","unstructured":"Martin P, Chen Z, Cheson BD,  Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. Br J Haematol 2017;178:250\u2013256.10.1111\/bjh.14667"},{"key":"B38","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond DA","year":"2020","unstructured":"Bond DA, Huang Y, Fisher JL,  Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 2020;34:3197\u20133205.10.1038\/s41375-020-0987-6"},{"key":"B39","series-title":"Blood","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119545","article-title":"\u201cSecondary chronic myeloid leukemia\u201d: comparison between patients previously exposed or not to chemo and\/or radiotherapy","volume":"132","author":"Autore F","year":"2018","unstructured":"Autore F, Sora F, Chiusolo P,  \u201cSecondary chronic myeloid leukemia\u201d: comparison between patients previously exposed or not to chemo and\/or radiotherapy. Blood 2018;132(Suppl 1):Abstract 632.10.1182\/blood-2018-99-119545"},{"key":"B40","series-title":"Indian J Pathol Microbiol","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4103\/0377-4929.125369","article-title":"Simultaneous occurrence of chronic myeloid leukemia and chronic lymphocytic leukemia: report of an unusual case","volume":"56","author":"Rahman K","year":"2013","unstructured":"Rahman K, George S, Mangal S,  Simultaneous occurrence of chronic myeloid leukemia and chronic lymphocytic leukemia: report of an unusual case. Indian J Pathol Microbiol 2013;56:453\u2013456.10.4103\/0377-4929.125369"},{"key":"B41","series-title":"Blood","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.1182\/blood-2010-08-301788","article-title":"Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia","volume":"117","author":"Buda-Okreglak EM","year":"2011","unstructured":"Buda-Okreglak EM, Cordaro DV. Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia. Blood 2011;117:5279.10.1182\/blood-2010-08-301788"},{"key":"B42","series-title":"J Med Case Reports","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13256-018-1612-4","article-title":"Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature","volume":"12","author":"Abuelgasim KA","year":"2018","unstructured":"Abuelgasim KA, Rehan H, Alsubaie M,  Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature. J Med Case Reports 2018;12:64.10.1186\/s13256-018-1612-4"},{"key":"B43","series-title":"Leuk Lymphoma","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1080\/1042819021000016140a","article-title":"Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia","volume":"43","author":"Salim R","year":"2002","unstructured":"Salim R, Wang L, Lin K,  Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia. Leuk Lymphoma 2002;43:2225\u20132227.10.1080\/1042819021000016140a"},{"key":"B44","series-title":"Haematologica","first-page":"253","article-title":"Simultaneous occurrence of chronic granulocytic leukemia and chronic lymphoid leukemia","volume":"72","author":"Leoni F","year":"1987","unstructured":"Leoni F, Ferrini PR, Castoldi GL,  Simultaneous occurrence of chronic granulocytic leukemia and chronic lymphoid leukemia. Haematologica 1987;72:253\u2013256."},{"key":"B45","series-title":"Clin Case Rep","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ccr3.974","article-title":"Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia","volume":"5","author":"Shea LK","year":"2017","unstructured":"Shea LK, Mikhail FM, Forero-Torres A,  Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia. Clin Case Rep 2017;5:899\u2013901.10.1002\/ccr3.974"},{"key":"B46","series-title":"Leuk Lymphoma","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1080\/10428194.2018.1547902","article-title":"Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases","volume":"60","author":"Boddu P","year":"2019","unstructured":"Boddu P, Gibbons J, Burger J,  Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma 2019;60:1568\u20131571.10.1080\/10428194.2018.1547902"},{"key":"B47","series-title":"Acta Haematol","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias","volume":"143","author":"Maiti A","year":"2020","unstructured":"Maiti A, Franquiz MJ, Ravandi F,  Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias. Acta Haematol 2020;143:567\u2013573.10.1159\/000506346"},{"key":"B48","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea DA","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL,  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med 2018;24:1859\u20131866.10.1038\/s41591-018-0233-1"},{"key":"B49","series-title":"Cancers (Basel)","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3390\/cancers13061311","article-title":"Targeting chronic myeloid leukemia stem\/progenitor cells using venetoclax-loaded immunoliposome","volume":"13","author":"Houshmand M","year":"2021","unstructured":"Houshmand M, Garello F, Stefania R,  Targeting chronic myeloid leukemia stem\/progenitor cells using venetoclax-loaded immunoliposome. Cancers (Basel) 2021;13:1311.10.3390\/cancers13061311"},{"key":"B50","series-title":"Sci Transl Med","doi-asserted-by":"publisher","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"8","author":"Leonard JT","year":"2016","unstructured":"Leonard JT, Rowley JS, Eide CA,  Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med 2016;8:354ra114.10.1126\/scitranslmed.aaf5309"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/2\/article-p102.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/2\/article-p102.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/2\/article-p102.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T20:12:20Z","timestamp":1676491940000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/2\/article-p102.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":50,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.7069","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}